AM Pharma
  • Home
  • About Us
    • About AM-Pharma
    • Leadership Team
    • Supervisory Board
    • Careers
  • Our approach
    • Our Product and MOA
    • Acute Kidney Injury (AKI)
    • Hypophosphatasia (HPP)
  • Partnering
  • Investors
  • Media Centre
    • Press Releases
    • Publications
  • Contact
  • Menu Menu

Home > Media Centre > Press Releases

Press releases

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

8th September 2021
AM-Pharma to receive EUR 20 million upfront payment, and…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2021-09-08 08:13:472021-09-08 08:13:47AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

6th July 2021
Utrecht, The Netherlands, 6 July, 2021 – AM-Pharma B.V., an…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2021-07-06 08:30:402021-07-09 08:40:25AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

1st July 2021
Utrecht, The Netherlands, 1 July 2021 – AM-Pharma B.V.,…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2021-07-01 12:44:002021-07-01 12:45:28AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

15th June 2021
Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2021-06-15 08:46:392021-07-09 08:47:24AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

7th January 2021
- First patients with COVID-19 enrolled in the REVIVAL Phase…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2021-01-07 10:01:062021-03-02 08:43:18AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

12th November 2020
- Trial to confirm potential of AM-Pharma’s recombinant alkaline…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2020-11-12 09:59:162020-11-12 10:00:10AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
Page 3 of 8‹12345›»
  • Privacy Policy
© AM-Pharma B.V.
Website by BTTR
linkedin
Scroll to top

We use cookies to help us improve our website by collecting and reporting information on how you use it. For more information about how we use cookies please see our Cookies Policy

AcceptReject


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only